



Attorney Docket No.: 6116.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Keith Anderson et al.

Application No.: 09/757,788

Group Art Unit: 1654

Filed: January 10, 2001

Examiner: Teller, Roy R

For: Transepithelial Delivery Of GLP-1 Derivatives

Confirmation No. 8259

#18  
H-Q-1  
7/12/03  
**RECEIVED**

JUN 25 2003

TECH CENTER 1600/2900

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the restriction requirement mailed May 19, 2003, Applicants elect the claims of group I, claims 1-8, drawn to peptides having the amino acid sequence of SEQ ID NO: 1 (ie the GLP-1 of formula II on pages 7-8 of the application), for continued prosecution and select the following species:

Arg34-GLP-1(7-37)-OH; the spacer gamma-GLU and Arg34Lys26(N-gamma-glutamyl(N-hexadecanoyl))) -GLP-1(7-37)-OH.

Respectfully submitted,

Date: June 19, 2003

Richard W. Bork  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800



23650

PATENT TRADEMARK OFFICE